Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial ...

Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

The appointment of Richard Pazdur, currently director of the FDA’s Oncology Center of Excellence, comes less than a week ...

The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for ...

Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts ...